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ABSTRACT
Introduction: Tetrabenazine (TBZ) reduces
chorea related to Huntington disease (HD);
however, it is uncertain whether this effect
improves functionally relevant motor skills
such as hand coordination and balance. The
objective of this study was to provide pilot data
regarding three motor function tests, which
might be useful in monitoring symptom
progression and therapeutic response, pending
formal validation.
Methods: The authors assessed 11 ambulatory
patients with HD-related chorea on two occasions:
(1) while off TBZ (eitherprior to starting therapy or
following a [24 h washout) and (2) when on a
stable dose of TBZ, titrated to optimal effect. Study
evaluations included the Jebsen-Taylor Hand
Function Test (JTHFT) and Berg Balance Scale, a
timed 25-foot walk, the Montreal Cognitive
Assessment (MoCA) and the complete United
Huntington Disease Rating Scale (UHDRS).
Results: Maximal chorea scores (UHDRS item
12) improved from 11.1 ± 2.9 to 8.5 ± 3.9 while
on TBZ (P = 0.03), but we could not detect an
improvement in functional measures while on
TBZ in this small cohort. Scores of the JTHFT
were globally slower than published normative
data and correlated with MoCA summary
scores, but not UHDRS chorea scores.
Conclusions: This pilot study did not detect
significant functional gains with chorea
suppression. The fact that performance on
tests of hand function correlates with MoCA
but not UHDRS chorea scores highlights the
need for additional treatments targeted toward
the cognitive aspects of HD.
J. M. Ferrara
Movement Disorder Clinic, Virginia Tech Carilion
School of Medicine and Research Institute, Roanoke,
VA, USA
G. Mostile  C. Hunter  J. Jankovic (&)
Department of Neurology, Parkinson Disease Center
and Movement Disorders Clinic, Baylor College of
Medicine, Houston, TX, USA
e-mail: josephj@bcm.tmc.edu
O. R. Adam
Division of Neurology, Naval Medical Center,
Portsmouth, VI, USA
Enhanced content for this article is
available on the journal web site:
www.neurologytherapy-open.com
123
Neurol Ther (2012) 1:5
DOI 10.1007/s40120-012-0005-7
Keywords: Berg Balance Scale; Chorea;
Huntington disease; Jebsen-Taylor Hand
Function Test; Tetrabenazine
INTRODUCTION
Huntington disease (HD) is an autosomal
dominant, neurodegenerative disorder
characterized by cognitive and behavioral
dysfunction, as well as various hyper- and
hypokinetic movement disorders, of which
chorea is generally most prominent. In
patients with HD, chorea has a deleterious
effect on coordinated limb movements [1, 2],
but its effect on overall motor function has not
been fully explored.
The pivotal trial that led to the Food and
Drug Administration’s approval of
tetrabenazine (TBZ) for the treatment of
chorea associated with HD showed that TBZ
significantly reduced chorea scores on the
Unified Huntington Disease Rating Scale
(UHDRS) [3], but the study could not
demonstrate a corresponding improvement in
the UHDRS functional assessment measures,
including the Total Functional Capacity Scale,
Functional Assessment Checklist, and
Independence Scale [4]. Indeed, Functional
Assessment Checklist scores worsened
significantly when compared to controls
(-6.3%, P = 0.02), and there was a small but
significant correlation between these scores
and parkinsonism, a potential side effect of
TBZ. TBZ also did not appear to lessen falls,
although fall rates did diminish in an open-
label extension study, which followed the trial
[3, 5]. Accordingly, questions remain as to
whether and how the antichorea effects of TBZ
impact functionally relevant motor skills. The
authors, therefore, conducted a pilot study to
evaluate tools that may be used to objectively




Eleven patients with HD (four women, mean
age 55 years; Table 1) were recruited from the
Baylor College of Medicine Parkinson Disease
Center and Movement Disorders Clinic in
Houston, TX, USA. The diagnosis of HD was
confirmed with genetic testing (CAG repeat
length [37 in the Htt gene) in either the
patient (n = 9) or a first-degree relative (n = 2).
All participants were independently ambulatory
and sufficiently disabled by chorea to justify
pharmacological intervention. No individuals
had used dopamine-receptor blocking drugs
within 30 days of enrollment. Antidepressants
and benzodiazepines were permitted, but only
at stable doses. Additional exclusionary criteria
were physical or psychiatric symptoms which
might render the patient unsafe to participate
in the study as determined by the investigator.
All patients signed an informed consent before
entering the study approved by Baylor College
of Medicine Internal Review Board for Human
Research.
Evaluation Procedures
In this open-label study, all patients were
assessed on two occasions within a 6-month
period: (1) while off TBZ and (2) when on a
stable dose of TBZ, as prescribed by each
patient’s treating physician (mean cumulative
daily dosage 62.5 ± 19.4 mg). The ‘‘off TBZ’’
evaluation was performed either prior to
starting therapy (n = 6) or following a [24 h
washout (n = 5, mean washout duration
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34.5 ± 4.5 h). All study instruments were scored
as per their published guidelines.
On-off study drug evaluations included the
Jebsen-Taylor Hand Function Test (JTHFT) [6],






Age at the evaluation 54.5 ± 13.7 [35–71]
Age of symptom onset 46.1 ± 11.7 [30–65]
Female gender 4 (36.4%)
Ethnicity
White, non-Hispanic 10 (90.9%)
Hispanic 1 (9.1%)
Education level (years) 13.6 ± 4.7 [3–20]











Verbal ﬂuency test (raw
score)
15.6 ± 8.1 [6–31]
Symbol digit modalities test
(raw score)



















Mood score 6.8 ± 5.8 [0–16]
Behavior score 4.5 ± 4.2 [0–14]
Psychosis score 0.8 ± 1.9 [0–6]




18.1 ± 5.1 [11–25]
Independence scale (IS) 75.5 ± 10.1 [60–95]
Total functional capacity
(TFC)d
6.5 ± 3.3 [3–11]
MoCA: cumulative scored 19.4 ± 5.4 [7–24]
BBS Berg Balance Scale, HD Huntington disease, JTHFT
Jebsen-Taylor Hand Function Test, MoCA Montreal
Cognitive Assessment, T25FW timed 25-foot walk test,
UHDRS United Huntington Disease Rating Scale
a CAG repeat length data were not available for two patients
b Behavioral assessment scores are the sum of frequency
and severity scores for corresponding items. For UHDRS
scoring, see Reference [3]
c The TFC is a 14-unit scale (range 0–13), which rates
capacity to hold employment, manage ﬁnances, complete
domestic chores, perform activities of daily living, and
reside independent of nursing care. The FAC is a 25-item
checklist, which includes a spectrum of common life
activities, such as walking, preparing meals, and driving.
Patients are scored either as able (1) or unable (0) to
complete each activity without help, and scores are
summated. The IS ranges from 10 to 100 units in
gradations of 5 units, with 10 representing total bed care
requiring enteral nutrition and 100 representing full
independence
d n = 10
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Berg Balance Scale (BBS) [7], a timed 25-foot
walk (T25FW) [8], and the motor section of the
UHDRS [4], which was video-recorded and
scored by a blinded rater. Before the scored
examinations, patients completed a trial run of
the JTHFT, BBS, and T25FW to ensure they fully
understood and were able to perform the tasks.
In addition to motor testing, patients
completed the Montreal Cognitive Assessment
(MoCA), a brief but sensitive screening tool for
mild cognitive impairment in HD [9]. The
authors also administered the cognitive,
behavioral, and functional portions of the
UHDRS [4]. The UHDRS functional assessment
consists of the Total Functional Capacity Scale,
Functional Assessment Checklist, and
Independence Scale (Table 1). On all UHDRS
functional scales, higher scores indicate better
functioning than lower scores. The short
duration of the study precludes a valid on-off
comparison of cognitive, behavioral, and
UHDRS functional items. Patients were
prospectively monitored for adverse events.
Data Analysis
Data were expressed as mean ± standard
deviation (range) for scalar measures and
frequency (percent) for categorical variables.
Changes in motor performance on and off TBZ
were assessed via parametric t-tests and Wilcoxon
signed-ranks test for not-normally distributed
variables. Pearson’s r and Spearman’s rho were
used to assess correlations between the JTHFT and
other variables including chorea scores and
cognitive parameters.
RESULTS
Demographic and nonmotor characteristics of
the study participants are described in Table 1,
and assessments of motor function on and off
TBZ are provided in Table 2. Maximal chorea
scores (UHDRS item 12) improved from
11.1 ± 2.9 to 8.5 ± 3.9 while on TBZ
(P = 0.03). In this small cohort, JTHFT
parameters, the BBS, and the T25FW were
similar in the on and off TBZ states.
Scores on the JTHFT were globally slower
than published normative data [6].
Of 77 JTHFT assessments performed off TBZ
for each hand (7 JTHFT items 9 11 subjects),
only 6.5% of dominant hand and 14.3% of
nondominant hand performances were normal,
i.e., within the 95% upper confidence limit.
Performance on the JTHFT correlated with
cognition, specifically the MoCA, but did not
correlate with UHDRS maximal chorea scores
(Table 3).
Patients reported no adverse effects related to
the TBZ washout apart from increased chorea.
Chronic use of TBZ was associated with mild
fatigue (two patients) and insomnia (one
patient).
DISCUSSION
Tetrabenazine is a benzoquinolizine derivative,
which depletes dopamine (and to a lesser extent
other biogenic amines) within the central
nervous system by reversibly inhibiting
presynaptic vesicular monoamine transporter
[10]. TBZ has been shown to reduce HD-related
chorea in several studies [10–15]. The TETRA-
HD [3], a multicenter double-blind placebo-
controlled trial, showed that TBZ provided a
mean reduction of 23.5% in chorea severity
when compared to placebo (P = 0.0001), and
this effect correlated with benefit in a global
measure of clinical outcome. However, it is not
clear whether the improvement in chorea score
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translates into improvement in overall motor
function.
Prior studies of HD have primarily utilized
the UHDRS to assess patient functional
parameters; specifically the Total Functional
Capacity Scale, Functional Assessment
Checklist, and Independence Scale. The
functional assessment portion of the UHDRS
has merits: it is easily administered, validated
[4], closely linked with health-related quality of
life [16], and able to predict the rate of future
decline [17]. The UHDRS functional
assessments, however, contain several
elements that are cognitively demanding; for
example, patients are rated on their ability to
maintain employment, drive, manage finances,
supervise children, and administer medications.
These items are relevant to HD, but they are
unlikely to illuminate any potential benefits in
function that arise from treating motor
symptoms including chorea. Other items
within the UHDRS functional battery are less
complex and perhaps more apt to improve with
suppression of chorea (e.g., dressing and
eating); however, the UHDRS appraises these
tasks in a manner that is insensitive to change.
Therefore, it is not surprising that
pharmacotherapies targeted toward chorea,
including TBZ, do not positively influence the
UHDRS functional assessments [3, 5, 17, 18] and
that progressive decline in these domains is
predicted predominantly by cognitive and
behavioral parameters [17, 19]. Given these
limitations, the authors explored the effect of
TBZ on motor function using the JTHFT, BBS,
and T25FW, three instruments in which
patients are assessed while performing motor
tasks.
In this pilot study, TBZ had little impact on
the time needed to complete tests of hand
function, and both walking speed and balance
were unchanged by treatment. The antichorea
effect of TBZ seen in the present study was less
than that found in the only large-scale, placebo-
controlled trial of the drug [3]. It is unknown
whether more robust control of chorea through
higher dosing would have yielded better
performance on the motor function tests that
were studied in the present study. The fact that
motor performance on the JTHFT correlated
with cognitive dysfunction but not chorea
severity suggests that factors apart from chorea
Table 3 Correlation between items of the JTHFT and the MoCA summary score
JTHFT MoCA total score
Dominant hand Nondominant hand
Writing -0.852 (0.002) -0.432 (0.2)
Simulated page turning -0.888 (0.001) -0.799 (0.006)
Lifting small, common objects -0.661 (0.04) -0.764 (0.01)
Simulated feeding -0.545 (0.1) -0.669 (0.03)
Stacking checkers -0.824 (0.003) -0.678 (0.03)
Lifting large, light objects -0.837 (0.003) -0.873 (0.001)
Lifting large, heavy objects -0.827 (0.003) -0.706 (0.02)
Data are correlation coefﬁcients (P values)
Evaluations performed off TBZ, n = 10
JTHFT Jebsen-Taylor Hand Function Test, MoCA Montreal Cognitive Assessment
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have a substantial impact on motor tasks.
Pertinent impairments might include
attention deficits and other deficiencies in
executive function [20, 21] as well as
impairments in the ability to automatize
behavior [22].
The authors recognize the methodological
limitations of the present study, including its
small sample size and open-label design.
Although a placebo-controlled study would be
preferable, the effect of placebo on the motor
features of HD is modest [23]. The use of a drug
washout to assess motor status off TBZ also
introduces potential problems, as withdrawal of
a therapy may not approximate a treatment
naive state; however, TBZ has a short half-life,
which makes a washout design feasible. In
animal studies, the drug is essentially
eliminated from the brain within 24 h of
withdrawal [24], and prior studies of patients
with HD have shown that chorea re-emerges
within a mean of 5 h following withdrawal [12].
The pharmacodynamic changes that follow
chronic administration of TBZ are not known;
however, TBZ washout does not appear to
intensify chorea beyond pretreatment levels,
and withdrawal is generally well-tolerated [3, 5,
14]. Phenotypic variability in HD also poses
challenges, as gains in motor function from
chorea suppression may be offset by worsening
bradykinesia and dystonia in some patients.
In conclusion, improved therapies for HD
must address clinically relevant endpoints,
including motor function. The present study
provides pilot data regarding three motor
function tests, which might be useful in
monitoring symptom progression and
therapeutic response, pending formal
validation. The fact that performance on tests
of hand function correlates with MoCA, but not
UHDRS chorea scores, highlights the need for
additional treatments targeted toward the
cognitive aspects of HD.
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